These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3957117)

  • 1. Immunosuppressive effects of peritoneal fluids from ovarian cancer patients.
    Onsrud M
    Gynecol Oncol; 1986 Mar; 23(3):316-22. PubMed ID: 3957117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive factors in ascites fluids from ovarian cancer patients.
    Fumita Y; Tanaka F; Saji F; Nakamuro K
    Am J Reprod Immunol (1980); 1984 Dec; 6(4):175-8. PubMed ID: 6528882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive activity of peritoneal fluid in women with endometriosis.
    Oosterlynck DJ; Meuleman C; Waer M; Koninckx PR; Vandeputte M
    Obstet Gynecol; 1993 Aug; 82(2):206-12. PubMed ID: 8336865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum-mediated immunosuppression: a possible tumor marker in patients with ovarian carcinoma.
    Onsrud M
    Gynecol Oncol; 1985 May; 21(1):94-100. PubMed ID: 3988128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Suppression of immunological response by ascitic fluid from gastrointestinal cancer patients].
    Amemiya K
    Nihon Geka Gakkai Zasshi; 1983 Dec; 84(12):1229-36. PubMed ID: 6201709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer.
    Berek JS; Bast RC; Lichtenstein A; Hacker NF; Spina CA; Lagasse LD; Knapp RC; Zighelboim J
    Obstet Gynecol; 1984 Nov; 64(5):708-14. PubMed ID: 6493663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppression related to ascitic fluid in patients with ovarian carcinoma.
    Marotti T; Hrsak I; Krusić J; Deverić G
    Oncology; 1982; 39(5):298-303. PubMed ID: 7048173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T lymphocytes and cytokine production in ascitic fluid of ovarian malignancies.
    Chen CK; Wu MY; Chao KH; Ho HN; Sheu BC; Huang SC
    J Formos Med Assoc; 1999 Jan; 98(1):24-30. PubMed ID: 10063270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer inhibitory substance produced by the peritoneal cells of patients with ovarian cancer.
    Lichtenstein AK; Berek J; Zighelboim J
    J Natl Cancer Inst; 1985 Feb; 74(2):349-55. PubMed ID: 3856049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of an immunosuppressive fraction from ascites fluid of patients with ovarian cancer on spontaneous and antibody-dependent cytotoxicity.
    Badger AM; Oh SK; Moolten FR
    Cancer Res; 1981 Mar; 41(3):1133-9. PubMed ID: 7193084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphokine-activated killer activity of tumor-associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumors.
    Allavena P; Zanaboni F; Rossini S; Merendino A; Bonazzi C; Vassena L; Mangioni C; Mantovani A
    J Natl Cancer Inst; 1986 Oct; 77(4):863-8. PubMed ID: 3489856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer.
    Hunter VJ; Weinberg JB; Haney AF; Soper JT; Lavin P; Metsch L; Knapp RC; Bast RC
    Gynecol Oncol; 1990 Feb; 36(2):161-5. PubMed ID: 2404835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer activity of lymphoid cells isolated from human ascitic ovarian tumors.
    Mantovani A; Allavena P; Sessa C; Bolis G; Mangioni C
    Int J Cancer; 1980 May; 25(5):573-82. PubMed ID: 6154662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mononuclear-cell infiltration in ovarian cancer. II. Immune function of tumour and ascites-derived inflammatory cells.
    Haskill S; Koren H; Becker S; Fowler W; Walton L
    Br J Cancer; 1982 May; 45(5):737-46. PubMed ID: 6177328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of cancerous ascites on natural killer activity].
    Shimura T; Fujimoto S; Ishigami H; Amemiya K; Takahashi O; Okui K
    Gan No Rinsho; 1983 Feb; 29(2):A-9, 133-7. PubMed ID: 6876401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural immunity against ovarian tumors.
    Lotzová E; Savary CA; Freedman R; Bowen JM
    Comp Immunol Microbiol Infect Dis; 1986; 9(2-3):269-75. PubMed ID: 3491727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppressive activity and tissue polypeptide antigen content of human ascitic fluids.
    Badger AM; Buehler RJ; Cooperband SR
    Cancer Res; 1978 Oct; 38(10):3365-70. PubMed ID: 688226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125).
    Belisle JA; Gubbels JA; Raphael CA; Migneault M; Rancourt C; Connor JP; Patankar MS
    Immunology; 2007 Nov; 122(3):418-29. PubMed ID: 17617155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detection of interferon-gamma in malignant peritoneal effusion in ovarian cancer patients].
    Hu XZ
    Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):245-9. PubMed ID: 1396070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FACS analysis of peritoneal lymphocytes in ovarian cancer and control patients.
    Reijnhart RM; Bieber MM; Teng NN
    Immunobiology; 1994 Aug; 191(1):1-8. PubMed ID: 7806256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.